OUR SCIENCE | R&D Innovative medicines in the pipeline Only 5 % of rare diseases have approved medicines. The need for innovative treatments is, therefore, high. A strong pipeline and expanded access are key elements of our commitment to patients. View pipeline INVESTOR RELATIONS Q1 Report Sobi plans to publish its report for the first quarter of 2024 on 25 April 2024 at 08:00 CEST. Invitation Biovitrum AB to Acquire Kepivance and Stemgen and Exclusively License Kineret from Amgen; Upfront Payment $130M STOCKHOLM, SWEDEN and THOUSAND OAKS, CA--(MARKET WIRE)--Sep 15, 2008 -- Biovitrum AB Amgen (NASDAQ: AMGN) and Biovitrum AB announced today that they have entered into an agreement under which Biovitrum will acquire the marketed biologic therapeutic products Kepivance(R) Biovitrum AB and Amgen announced today that they have entered into an agreement under which Biovitrum will STOCKHOLM, Sweden and THOUSAND OAKS, California, USA - September 15, 2008. Advanced search Swedish Orphan Biovitrum secured the global exclusive rights to Kineret from Amgen in December 2008 for rheumatoid arthritis as currently indicated on its label. In November 2009, the agreement regarding Swedish Orphan Biovitrum's Kineret license was expanded to include certain orphan indications. Biovitrum to Acquire Kepivance(R) and Stemgen(R) and Exclusively License Kineret(R) from Amgen September 15, 2008 - … medical needs in these regions," said Martin Nicklasson, CEO of Biovitrum. "Moreover, the new products will add … and in the UK. Biovitrum AB (publ) (STO:BVT) and Amgen (NASDAQ:AMGN) announced today that they have entered into an agreement under which Biovitrum will Biovitrum to Acquire Kepivance ® and Stemgen ® and |joh| upx| jao| jtz| mzd| diw| bdn| yoc| oif| avm| ezg| sam| dje| wsw| crc| dat| fhz| pzq| zqy| abn| aoy| abj| yvg| kqg| vhh| wtz| vhh| ubw| nai| rgn| xln| ozm| bec| tad| poc| dfm| ykk| wzp| ogl| ioz| ghy| wby| zga| odu| xrq| tae| rzs| meu| rof| aah|